{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:10:21Z","timestamp":1756368621451,"version":"3.44.0"},"reference-count":11,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,7,4]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Plasma cell leukaemia (PCL) is an aggressive haematological malignancy which is classified into primary (pPCL) and secondary PCL. A 39-year-old Indian man presented to the Department of Hematology with a 2-week history of fever and lethargy. Clinically, he was pale and febrile. Haemogram revealed bicytopenia with leucocytosis. The peripheral blood film portrayed rouleax formation with 45% of circulating plasma cells. Serum protein electrophoresis and immunofixation revealed IgG lambda paraproteinaemia of 48\u2009g\/L. Bone marrow aspirate, flow cytometry and trephine were consistent with IgG lambda pPCL. He was treated with six cycles of bortezomib, thalidomide and dexamethasone combination chemotherapy followed by high-dose melphalan conditioning and autologous stem cell transplant. Currently, he is in complete remission for the past 18 months and is on oral lenalidomide maintenance therapy. Prognosis is often dismal in pPCL with the median overall survival below 1\u2009year if treatment is delayed.<\/jats:p>","DOI":"10.1136\/bcr-2020-235543","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T07:06:24Z","timestamp":1595574384000},"page":"e235543","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Primary plasma cell leukaemia in a 39-year-old man"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-9261","authenticated-orcid":false,"given":"Ganesh","family":"Kasinathan","sequence":"first","affiliation":[{"name":"Hematology, Ampang Hospital, Ampang, Selangor, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"2025082800443272000_13.7.e235543.1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.133.5.813"},{"key":"2025082800443272000_13.7.e235543.2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garc\u00eda-Sanz","year":"1999","journal-title":"Blood"},{"key":"2025082800443272000_13.7.e235543.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70125-8"},{"key":"2025082800443272000_13.7.e235543.4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/ccr3.2339","article-title":"Primary plasma cell leukemia: a case report and review of the literature","volume":"7","author":"Ngu","year":"2019","journal-title":"Clin Case Rep"},{"key":"2025082800443272000_13.7.e235543.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565051"},{"key":"2025082800443272000_13.7.e235543.6","unstructured":"Swerdlow SH , Campo E , Harris NL , et al . WHO classification of tumours of haematopoietic and lymphoid tissues (revised). 4th edn. Lyon: IARC, 2017."},{"key":"2025082800443272000_13.7.e235543.7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.4"},{"key":"2025082800443272000_13.7.e235543.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.01.005"},{"key":"2025082800443272000_13.7.e235543.9","doi-asserted-by":"crossref","first-page":"79517","DOI":"10.18632\/oncotarget.18535","article-title":"The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"2025082800443272000_13.7.e235543.10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating BCL-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025082800443272000_13.7.e235543.11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.241"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:44:39Z","timestamp":1756367079000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,23]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/bcr-2020-235543"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235543","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}